Pelle G Lindqvist1, Katarina Bremme, Margareta Hellgren. 1. Department of Obstetrics and Gynecology, Clintec, Karolinska University Hospital, Huddinge, Kvinnokliniken K57, Stockholm, Sweden. pelle.lindqvist@ki.se
Abstract
OBJECTIVE: To study the efficacy of thromboprophylaxis with low molecular weight heparin (LMWH) in pregnant women with one previous venous thromboembolic event (VTE). Secondary aims were to study the long-term risk of secondary recurrence, bleeding and obstetric complications. DESIGN: A prospective national study of long-term LMWH thromboprophylaxis in Sweden. SETTINGS: All hospitals in Sweden during January 1998-December 2002, PARTICIPANTS: Pregnant women with one previous VTE and controls drawn from the Swedish Medical Birth Registry. The women were cross-matched with the Swedish Hospital Discharge Register to identify all recurrences and to ascertain the annual risk of recurrence. MAIN OUTCOME MEASURES: Recurrence of VTE, bleeding complications at delivery and obstetric complications. RESULTS: 326 of 393 registered women could be evaluated. The relative risk reduction in VTE was 88%. There was an absolute increased risk of VTE during the thromboprophylaxis period: 1.2% compared to 0.2% among controls (p<0.001). The risk during the immediate post-treatment period (43-100 days post-partum) was increased 28-fold. The annual incidence of VTE after delivery was 1%. The risk of hematoma and major blood loss at delivery was increased during thromboprophylaxis (p<0.001). There were no differences in the incidences of preeclampsia, intrauterine growth restriction or placental abruption. CONCLUSIONS: The relative risk reduction in VTE during thromboprophylaxis was 88%. After pregnancy, the annual long-term risk of recurrence was 1%. The risk was most pronounced in the post-treatment period. There was an increased risk of bleeding complications among women given LMWH, but there was no effect on obstetric complications.
OBJECTIVE: To study the efficacy of thromboprophylaxis with low molecular weight heparin (LMWH) in pregnant women with one previous venous thromboembolic event (VTE). Secondary aims were to study the long-term risk of secondary recurrence, bleeding and obstetric complications. DESIGN: A prospective national study of long-term LMWH thromboprophylaxis in Sweden. SETTINGS: All hospitals in Sweden during January 1998-December 2002, PARTICIPANTS: Pregnant women with one previous VTE and controls drawn from the Swedish Medical Birth Registry. The women were cross-matched with the Swedish Hospital Discharge Register to identify all recurrences and to ascertain the annual risk of recurrence. MAIN OUTCOME MEASURES: Recurrence of VTE, bleeding complications at delivery and obstetric complications. RESULTS: 326 of 393 registered women could be evaluated. The relative risk reduction in VTE was 88%. There was an absolute increased risk of VTE during the thromboprophylaxis period: 1.2% compared to 0.2% among controls (p<0.001). The risk during the immediate post-treatment period (43-100 days post-partum) was increased 28-fold. The annual incidence of VTE after delivery was 1%. The risk of hematoma and major blood loss at delivery was increased during thromboprophylaxis (p<0.001). There were no differences in the incidences of preeclampsia, intrauterine growth restriction or placental abruption. CONCLUSIONS: The relative risk reduction in VTE during thromboprophylaxis was 88%. After pregnancy, the annual long-term risk of recurrence was 1%. The risk was most pronounced in the post-treatment period. There was an increased risk of bleeding complications among women given LMWH, but there was no effect on obstetric complications.
Authors: Alyshah Abdul Sultan; Matthew J Grainge; Joe West; Kate M Fleming; Catherine Nelson-Piercy; Laila J Tata Journal: Blood Date: 2014-08-25 Impact factor: 22.113
Authors: Shannon M Bates; Anita Rajasekhar; Saskia Middeldorp; Claire McLintock; Marc A Rodger; Andra H James; Sara R Vazquez; Ian A Greer; John J Riva; Meha Bhatt; Nicole Schwab; Danielle Barrett; Andrea LaHaye; Bram Rochwerg Journal: Blood Adv Date: 2018-11-27
Authors: Anna Sandström; Sven Cnattingius; Anna-Karin Wikström; Olof Stephansson; Anastasia N Iliadou Journal: PLoS One Date: 2015-10-14 Impact factor: 3.240